Last reviewed · How we verify
CNS Stimulant
CNS Stimulant is a CNS stimulant Small molecule drug developed by Milton S. Hershey Medical Center. It is currently FDA-approved for Attention-deficit/hyperactivity disorder (ADHD), Narcolepsy, Fatigue or excessive daytime somnolence. Also known as: CNS Simulant RCT phase (second phase).
CNS stimulants increase the activity of the central nervous system by enhancing the release or blocking the reuptake of neurotransmitters such as dopamine and norepinephrine.
CNS Stimulants, such as Extended Release Methylphenidate (OROS-Methylphenidate), are used to treat conditions including Attention Deficit Disorder With Hyperactivity and Substance Use Disorders. They are also being studied for their potential in addressing Opioid Use Disorder and Overdose.
At a glance
| Generic name | CNS Stimulant |
|---|---|
| Also known as | CNS Simulant RCT phase (second phase) |
| Sponsor | Milton S. Hershey Medical Center |
| Drug class | CNS stimulant |
| Modality | Small molecule |
| Therapeutic area | Neurology / Psychiatry |
| Phase | FDA-approved |
Mechanism of action
CNS stimulants work primarily through monoaminergic pathways, either by promoting the release of catecholamines (dopamine and norepinephrine) from presynaptic neurons or by inhibiting their reuptake at the synaptic cleft. This results in increased synaptic concentrations of these neurotransmitters, leading to enhanced neural signaling, increased alertness, improved focus, and elevated mood. Common mechanisms include sympathomimetic activity and inhibition of monoamine oxidase or reuptake transporters.
Approved indications
- Attention-deficit/hyperactivity disorder (ADHD)
- Narcolepsy
- Fatigue or excessive daytime somnolence
Common side effects
- Insomnia
- Nervousness or anxiety
- Headache
- Increased heart rate or palpitations
- Appetite suppression
- Tremor
Key clinical trials
- Substance Misuse To Psychosis for Stimulants (PHASE2, PHASE3)
- Dronabinol in Total Knee Arthroplasty (TKA) (PHASE4)
- Kentucky Women's Justice Community Overdose Innovation Network - Phase II (NA)
- Developing and Testing Innovative Care Pathways for Screening and Treatment of OUD/PTSD in Jails (NA)
- Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol (PHASE3)
- Health Outcomes by Neighborhood - Baltimore
- LDART for Stimulant Use Disorder (NA)
- Predictors of Improvements in Irritability and Aggression in Children With ADHD Treated With CNS Stimulants (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CNS Stimulant CI brief — competitive landscape report
- CNS Stimulant updates RSS · CI watch RSS
- Milton S. Hershey Medical Center portfolio CI
Frequently asked questions about CNS Stimulant
What is CNS Stimulant?
How does CNS Stimulant work?
What is CNS Stimulant used for?
Who makes CNS Stimulant?
Is CNS Stimulant also known as anything else?
What drug class is CNS Stimulant in?
What development phase is CNS Stimulant in?
What are the side effects of CNS Stimulant?
Related
- Drug class: All CNS stimulant drugs
- Manufacturer: Milton S. Hershey Medical Center — full pipeline
- Therapeutic area: All drugs in Neurology / Psychiatry
- Indication: Drugs for Attention-deficit/hyperactivity disorder (ADHD)
- Indication: Drugs for Narcolepsy
- Indication: Drugs for Fatigue or excessive daytime somnolence
- Also known as: CNS Simulant RCT phase (second phase)
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing